Belgium

In November 2023, the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) announced the budget reduction for reimbursement of clinical laboratory services by 15% from January 2024. INAMI-RIZIV considers this reimbursement still sufficient and will reallocate released funds to other projects in health care. The reduction will not impact molecular biological and genetic testing.

In October 2023, the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) introduced an updated application procedure for the List of implants and invasive medical devices, including a new application form. The new form is organized according to the PICO (Population-Intervention-Comparator-Outcome) principle.

In late June 2023, the Belgian Health Care Knowledge Center (KCE) published a report on relevance of transversal budget impact analysis. This type of analysis should be submitted as part of the application to the National Institute for Health and Disability Insurance (INAMI-RIZIV) to obtain reimbursement for implants and invasive medical devices.

In July 2023, the National Institute for Health and Disability Insurance (INAMI-RIZIV) significantly updated the process to obtain reimbursement for health apps. More stakeholders, including the industry, can now submit an application to INAMI-RIZIV for temporary or permanent reimbursement. The new process will come into force on October 1, 2023.

In late June 2023, the National Institute for Health and Disability Insurance (INAMI-RIZIV) decided to extend reimbursement for molecular biology tests by next-generation sequencing (NGS) for one year until June 30, 2024. NGS in oncology and hemato-oncology are temporarily reimbursed as a pilot under a specific agreement (Convention) with INAMI-RIZIV from 2019.

On July 1, 2023, the National Institute for Health and Disability Insurance (INAMI-RIZIV) updated the conditions of reimbursement for continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM, commonly called flash glucose monitoring, FGM). Full coverage by health insurance became available to more patient categories.

In June 2023, the Belgian Health Care Knowledge Center (KCE) published Health Services Research concerning the performance of the Belgian healthcare system. KCE regularly conducts such "check-ups" of the healthcare system in collaboration with Sciensano, the National Institute for Health and Disability Insurance (INAMI/RIZIV), and the FPS Public Health. The conceptual framework and the list of performance indicators were revised and updated.

On June 8, 2023, Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) published an updated List of reimbursable devices and Nominative lists of brands to come into force on July 1, 2023. Three new material codes concerning cardiovascular and spinal procedures were introduced. Several new branded devices were registered on the Nominative Lists connected to new and already existing material codes.

On June 6, 2023, Belgian National Institute for Health and Disability Insurance (INAMI/RIZIV) introduced a new convention to reimburse aspirational and mechanical thrombectomy catheters for arterial thrombosis, deep vein thrombosis, arteriovenous fistula, and pulmonary embolism. Funding will only be provided if there is a shortage of thrombolytic drugs in Belgium.

In March 2023, the National Institute for Health and Disability Insurance (INAMI-RIZIV) updated the List of reimbursable devices and Nominative lists to take effect on April 1, 2023. Eight new codes for intracardiac transcatheter pacing systems with the corresponding conditions of reimbursement were added to the List, and two devices (Micra VR and Micra AV) were registered on the list of brands connected to that new codes.

On March 1, 2023, Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) updated three Articles of the Nomenclature related to in-vitro diagnostics. Twelve new codes concerning clinical biology, molecular biology for infections, and genetics were implemented.

In February 2023, the National Institute for Health and Disability Insurance (INAMI-RIZIV) announced the completion of a pilot project for gene expression profiling (GEP) tests in early-stage breast cancer, which ran from 2019. The pilot showed significant benefits, and INAMI-RIZIV launched a reimbursement for certain tests under the specific agreement (GEP convention) with healthcare providers.